Company Profile

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorder. It is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company's pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.

Employees

Sector

Biotechnology & Medical Research

More about the company

25/09/23	Regeneron Pharmaceuticals Completes Acquisition of Decibel Therapeutics	MT
25/09/23	Decibel Therapeutics, Inc. Announces Board Changes	CI
25/09/23	Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from NASDAQ Composite Index	CI
25/09/23	Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from S&P TMI Index	CI
25/09/23	Regeneron Pharmaceuticals, Inc. acquired remaining 91.65% stake in Decibel Therapeutics, Inc. from a group of shareholders.	CI
25/08/23	Decibel Therapeutics' Gene Therapy Candidate Granted US FDA's Fast-Track Designation	MT
25/08/23	Decibel Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation for DB-OTO	CI
11/08/23	Decibel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
10/08/23	Global markets live: Allianz, Generali, Sony, Disney, Alibaba...
10/08/23	Baird Downgrades Decibel Therapeutics to Neutral From Outperform, Adjusts Price Target to $5.25 From $21	MT
09/08/23	Sector Update: Health Care Stocks Advancing in Late Afternoon Trading	MT
09/08/23	Top Midday Gainers	MT
09/08/23	Regeneron Pharmaceuticals Signs Agreement to Acquire Decibel Therapeutics at $4 per Share	MT

10/08/23	Baird Downgrades Decibel Therapeutics to Neutral From Outperform, Adjusts Price Target to $5.25 From $21	MT
09/08/23	HC Wainwright Downgrades Decibel Therapeutics to Neutral From Buy	MT
15/03/23	SVB Securities Downgrades Decibel Therapeutics to Market Perform From Outperform, Adjusts Price Target to $2 From $7	MT
23/01/23	SVB Securities Adjusts Price Target on Decibel Therapeutics to $7 From $10, Maintains Outperform Rating	MT
10/11/22	Citigroup Adjusts Price Target on Decibel Therapeutics to $10 From $12, Maintains Buy Rating	MT

25/09/23	Decibel Therapeutics : Acquisition/Asset Disposal - Form 8-K	PU
05/09/23	DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX	BU
14/08/23	Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update	AQ
12/08/23	DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX	BU
11/08/23	Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update	GL

10/08/23	EN DIRECTO DESDE LOS MERCADOS: Rheinmetall, Allianz, Novo Nordisk, Walt Disney, Sony, KBC, Siemens, Meta, Ahold...
10/08/23	Bolsa de Madrid: ¡Todo en aumento, mi pobre señorita!
10/08/23	En Direct des Marchés : Alstom, Tapestry, Walt Disney, Sony, KBC, Siemens, Meta, Ahold...
10/08/23	Tout augmente, ma pauvre dame !

Manager	Title	Age	Since
Robert Landry DFI	Director of Finance/CFO	62	22/09/2023
Nouhad Husseini PRN	Corporate Officer/Principal	-	22/09/2023
Leonard Brooks TRE	Treasurer	-	22/09/2023

Decibel Therapeutics, Inc. Stock

Stocks

DBTX

US24343R1068

Biotechnology & Medical Research

Latest news : Decibel Therapeutics, Inc.

Analysts' recommendations: Decibel Therapeutics, Inc.

Press Releases: Decibel Therapeutics, Inc.

News in other languages: Decibel Therapeutics, Inc.

Quotes and Performance

Managers and Directors: Decibel Therapeutics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
25/09/23	John Lee	Issuer sale	Chief Development Officer	476,647	1.8970%
25/09/23	Kevin McLaughlin	Issuer sale	Director	30,000	0.1194%
25/09/23	Anna Trask	Issuer sale	Chief People Officer	341,666	1.3598%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DECIBEL THERAPEUTICS, INC.	-0.81%	-3.73%	-	-	124M
LONZA GROUP AG	+1.44%	+1.71%	-10.63%	-9.16%	43.13B
REVOLUTION MEDICINES, INC.	+3.31%	+5.93%	+308.19%	+562.02%	34.65B
BEONE MEDICINES AG	+2.84%	+2.14%	+6.87%	+34.93%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.54%	+8.51%	-22.34%	28B
CELLTRION, INC.	-1.90%	-1.56%	+11.62%	+19.80%	24.45B
ASCENDIS PHARMA A/S	-0.14%	+5.86%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-1.53%	+52.04%	+107.47%	13.14B
EUROFINS SCIENTIFIC SE	-0.57%	-2.43%	+5.18%	+4.20%	12.53B
IONIS PHARMACEUTICALS, INC.	-0.26%	+1.15%	+100.27%	+80.69%	12.25B
Average	+0.29%	+0.73%	+60.26%	+97.20%	23.61B
Weighted average by Cap.	+0.77%	+1.27%	+65.22%	+113.23%